Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
Voyager Therapeutics (Nasdaq: VYGR) announced the presentation of preclinical data from its vectorized antibody program at the 26th Annual Society for Neuro-Oncology Meeting on Nov. 19, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Voyager Therapeutics (Nasdaq: VYGR) announced the presentation of preclinical data from its vectorized antibody program at the 26th Annual Society for Neuro-Oncology Meeting on Nov. 19, 2021. The presentation, titled AAV mediated brain delivery of an ADCC-enhanced antibody obviates xenograft growth in mouse models of HER2+ breast cancer brain metastasis, will be delivered by Dan R. Laks, Ph.D., at 4:15 p.m. ET. This represents a significant advancement in the development of AAV gene therapy technology, aiming to treat severe diseases through innovative approaches.
Positive
- Presentation of preclinical data at a notable industry event highlights ongoing research efforts.
- Focus on HER2+ breast cancer brain metastasis indicates potential market expansion into oncology.
Negative
- None.
Details
News Market Reaction – VYGR
The recorded move for VYGR in the trading session of this news was -3.80%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced it will present preclinical data from its vectorized antibody program at the 26th Society for Neuro-Oncology (SNO) Annual Meeting on Nov. 19, 2021.
SNO Oral Presentation Details:
Title: AAV mediated brain delivery of an ADCC-enhanced antibody obviates xenograft growth in mouse models of HER2+ breast cancer brain metastasis
Abstract Number: EXTH-02
Abstract Session: CNS Metastases
Presenter: Dan R. Laks, Ph.D., Scientist II, Voyager Therapeutics
Presentation Time: 4:15 p.m. ET
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACERTM screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurologic disorders and other therapeutic areas. voyagertherapeutics.com LinkedIn Twitter
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.